226 related articles for article (PubMed ID: 32459423)
1. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
2. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
3. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
4. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
5. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
[No Abstract] [Full Text] [Related]
7. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
8. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
Muhammad J; Yusof Y; Ahmad I; Norhayati MN
BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
[TBL] [Abstract][Full Text] [Related]
9. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist.
Taylor HS; Giudice LC; Lessey BA; Abrao MS; Kotarski J; Archer DF; Diamond MP; Surrey E; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Rowan JP; Duan WR; Ng J; Schwefel B; Thomas JW; Jain RI; Chwalisz K
N Engl J Med; 2017 Jul; 377(1):28-40. PubMed ID: 28525302
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.
Muneyyirci-Delale O; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg E; Gillispie V; Hurtado S; Kim JH; Wang A; Wang H; Stewart EA
F S Rep; 2021 Sep; 2(3):338-346. PubMed ID: 34553161
[TBL] [Abstract][Full Text] [Related]
15. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
17. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies.
Surrey E; Taylor HS; Giudice L; Lessey BA; Abrao MS; Archer DF; Diamond MP; Johnson NP; Watts NB; Gallagher JC; Simon JA; Carr BR; Dmowski WP; Leyland N; Singh SS; Rechberger T; Agarwal SK; Duan WR; Schwefel B; Thomas JW; Peloso PM; Ng J; Soliman AM; Chwalisz K
Obstet Gynecol; 2018 Jul; 132(1):147-160. PubMed ID: 29889764
[TBL] [Abstract][Full Text] [Related]
20. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
